143 related articles for article (PubMed ID: 19492493)
1. Bisphosphonates and atrial fibrillation.
Prescrire Int; 2008 Aug; 17(96):161. PubMed ID: 19492493
[No Abstract] [Full Text] [Related]
2. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
3. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
4. Alendronate and atrial fibrillation.
Cummings SR; Schwartz AV; Black DM
N Engl J Med; 2007 May; 356(18):1895-6. PubMed ID: 17476024
[No Abstract] [Full Text] [Related]
5. Yearly zoledronic acid in postmenopausal osteoporosis.
Karam R; Camm J; McClung M
N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
[No Abstract] [Full Text] [Related]
6. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and the risk of atrial fibrillation.
Sewerynek E; Stuss M
Endokrynol Pol; 2011; 62(1):93-6. PubMed ID: 21365587
[TBL] [Abstract][Full Text] [Related]
8. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
9. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
10. Yearly zoledronic acid in postmenopausal osteoporosis.
Poole KE; Kaptoge S; Reeve J
N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
[No Abstract] [Full Text] [Related]
11. [Alendronate].
Lindberg M
Ugeskr Laeger; 1998 Oct; 160(44):6367-8. PubMed ID: 9810249
[No Abstract] [Full Text] [Related]
12. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
Konsta M; Bournia VK; Dania V; Iliopoulos A
J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
[No Abstract] [Full Text] [Related]
13. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
14. Considering competing risks . . . Not all black and white.
Cauley JA; Ensrud KE
Arch Intern Med; 2008 Apr; 168(8):793-5. PubMed ID: 18443252
[No Abstract] [Full Text] [Related]
15. Atrial fibrillation and bisphosphonate therapy.
Pazianas M; Compston J; Huang CL
J Bone Miner Res; 2010 Jan; 25(1):2-10. PubMed ID: 20091928
[TBL] [Abstract][Full Text] [Related]
16. [Osteoporosis medications. Bisphosphonates exceed the others].
MMW Fortschr Med; 2003 Oct; 145(42):66. PubMed ID: 14655453
[No Abstract] [Full Text] [Related]
17. [Alendronate].
Sørensen HA; Hyldstrup L
Ugeskr Laeger; 1998 May; 160(22):3240-3. PubMed ID: 9621809
[No Abstract] [Full Text] [Related]
18. Bisphosphonate-associated scleritis: a case report and review.
Leung S; Ashar BH; Miller RG
South Med J; 2005 Jul; 98(7):733-5. PubMed ID: 16108245
[TBL] [Abstract][Full Text] [Related]
19. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
20. Bisphosphonate use in osteoporosis: cardiovascular effects.
Gallagher JC; Sai AJ
Menopause; 2010; 17(1):5-7. PubMed ID: 19934778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
